AffiliationCancer Research UK Oncology Unit, Cancer Sciences Division, School of Medicine, Southampton General Hospital, Southampton SO16 6YD, UK.
MetadataShow full item record
AbstractNormal, bi-directional interactions between CD 40 and its natural ligand CD 154 (CD 40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD 40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal antibodies directed against CD 40 allows effective targeting of malignant cells through multiple mechanisms that include the recruitment of immune effector mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, direct anti-proliferative effects on neoplastic cells and, importantly, by the activation of tumor-targeted cellular cytotoxicity. This review provides the background to the early clinical trial data that are now beginning to emerge for this potentially exciting new treatment approach.
CitationAnti-CD 40 monoclonal antibody. 2005, 46 (8):1105-13 Leuk. Lymphoma
JournalLeukemia & Lymphoma
- Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
- Authors: Vitale LA, Thomas LJ, He LZ, O'Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, Baronas AR, Gergel LE, Boyer JM, Sisson C, Goldstein J, Marsh HC Jr, Keler T
- Issue date: 2019 Feb
- CD40 activation as potential tool in malignant neoplasms.
- Authors: Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR
- Issue date: 2002 Sep-Oct
- CD40 pathway blockade as an approach to immunotherapy.
- Authors: Burkly LC
- Issue date: 2001
- CD40L gene transfer in immunotherapy of cancer: more than co-stimulation?
- Authors: Bergmann C, Brandau S
- Issue date: 2009 Jan
- The Use of Anti-CD40 mAb in Cancer.
- Authors: Remer M, White A, Glennie M, Al-Shamkhani A, Johnson P
- Issue date: 2017